FAQ: TransCode Therapeutics Completes Phase 1a Trial of TTX-MC138 Cancer Treatment
Summary
TransCode Therapeutics has successfully completed Phase 1a clinical trials for TTX-MC138, an investigational microRNA-10b inhibitor, achieving primary safety endpoints and establishing a recommended Phase 2 dose with 44% of patients showing stable disease lasting four months or longer.
What is TTX-MC138 and what does it treat?
TTX-MC138 is an investigational inhibitor of microRNA-10b designed to treat metastatic tumors that overexpress microRNA-10b, which is a well-documented biomarker of metastasis.
What were the key results from the Phase 1a clinical trial?
The trial treated 16 patients with no significant safety events or dose-limiting toxicities observed, and 44% of patients achieved stable disease lasting four months or longer, establishing a recommended Phase 2 dose.
Why is this clinical trial completion significant?
This represents an important milestone as the treatment achieved its primary safety endpoint and demonstrated favorable safety, durability, and pharmacodynamic data, supporting advancement to Phase 2 evaluation for multiple metastatic cancer indications.
What is TransCode Therapeutics and what is their focus?
TransCode Therapeutics is a clinical-stage oncology company focused on treating metastatic disease through the intelligent design and effective delivery of RNA therapeutics based on their proprietary TTX nanoparticle platform.
What happens next for TTX-MC138?
Based on the favorable Phase 1a results, TTX-MC138 will advance into a Phase 2a trial to further assess efficacy across multiple metastatic cancer indications.
How many patients participated in the Phase 1a trial and what was the safety profile?
Sixteen patients were treated in the Phase 1a trial with no significant safety events or dose-limiting toxicities observed, achieving the primary safety endpoint.
What is the TTX nanoparticle platform?
The TTX nanoparticle platform is TransCode’s proprietary technology designed to overcome the challenges of RNA delivery, enabling therapeutic access to various novel genetic targets relevant to treating different cancers.
Where can investors find more information about TransCode Therapeutics?
The latest news and updates relating to RNAZ (TransCode’s stock symbol) are available in the company’s newsroom at https://ibn.fm/RNAZ.
What types of cancer could TTX-MC138 potentially treat?
TTX-MC138 is designed to treat metastatic tumors that overexpress microRNA-10b, and the upcoming Phase 2a trial will assess efficacy across multiple metastatic cancer indications.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 251905